RxDoctor Payments Data

Ignacio Valdes, MD

Internal Medicine · Deerfield Beach, FLNPI 1073591483

Payments from drug & device makers

$1,617in general payments, 2019–2025

Across 60 payments — averaging $26.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$589
  • Johnson & Johnson$351
  • Medtronic$299
  • Amgen$76
  • Pfizer$75
  • Lilly USA, LLC$70
  • plus $155 from 4 others

What the payments were for

  • Food & beverage$1,617100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,617 in reported general payments places this provider in the 75th percentile of 8,530 internal medicine providers in Florida.

See all internal medicine providers in Florida

Medicare billing

Part B allowed, 2024
$82,432
Medicare patients
423
Services billed
1,063

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban103$83,982
OzempicSemaglutide59$80,143
XareltoRivaroxaban39$34,043
MounjaroTirzepatide11$18,074
Trelegy ElliptaFluticasone/Umeclidin/Vilanter19$10,728
Tresiba Flextouch U-100Insulin Degludec14$10,487
TradjentaLinagliptin15$9,690
EntrestoSacubitril/Valsartan11$8,551
MyrbetriqMirabegron14$6,788
JanuviaSitagliptin Phosphate12$6,646
Repatha SureclickEvolocumab12$6,429
Rosuvastatin Calcium363$5,119
Ezetimibe83$2,524
Losartan Potassium161$2,216
Bisoprolol Fumarate73$2,139

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$75$83,982103 claims
Novo NordiskOzempic$589$80,14359 claims
Johnson & JohnsonXarelto$351$34,04339 claims
Lilly USA, LLCMounjaro$70$18,07411 claims
Boehringer IngelheimTradjenta$53$9,69015 claims
AbbVieSynthroid$44$1,45817 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 8,530 internal medicine providers in Florida.

Other internal medicine in Deerfield Beach

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →